# Limula

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/limula

- Industry: Biotechnology
- Headquarters: Switzerland, Switzerland
- Website: www.limula.ch
- Total disclosed funding: $6.8M
- Latest round: Seed (May 21, 2024)
- Investors on record: 6

## About

Founded in 2020 by co-founders Luc Henry, Yann Pierson, and Thomas Eaton and based in Switzerland, Limula, SA, provides a gene therapy platform to produce cancer treatments. In May 2024, Limula SA raised CHF 6.2 million in seed funding led by investor LifeX Ventures, with participation from other investors Verve Ventures, Zühlke Ventures, Oxford Seed Fund, Lichtsteiner Foundation, and W.A. de Vigier Foundation.
 
Limula's core product is a single-unit bioreactor that combines cell processing and centrifugation functionalities to eliminate the need for multiple devices and simplify the manufacturing workflow. The system is designed for automated operation, minimising human intervention and the potential for errors. The platform is modular, allowing for customisation and future expansion with additional functionalities. The bioreactor can be adapted for various production scales, from development to large-scale manufacturing.
 
The company will use the May 2024 funding to accelerate Limula's software.

## Funding rounds

- Seed, May 21, 2024, $6.8M — Zuhlke Ventures, LifeX Ventures, Lichtsteiner Foundation, Verve Ventures, Oxford Seed Fund, W.A. De Vigier Stiftung

## Investors

- Zuhlke Ventures (https://capitalatlas.ai/funds/zuhlke-ventures) — Seed
- LifeX Ventures (https://capitalatlas.ai/funds/lifex-ventures) — Seed
- Lichtsteiner Foundation — Seed
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Seed
- Oxford Seed Fund (https://capitalatlas.ai/funds/oxford-seed-fund) — Seed
- W.A. De Vigier Stiftung — Seed